Cargando…
Medullary thyroid carcinoma – Adverse events during systemic treatment: risk-benefit ratio
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from parafollicular C cells of the thyroid and associated with mutations in the proto-oncogene REarranged during Transfection (RET). The prognosis of MTC depends on clinical stage, with a 95.6% 10-year survival rate among p...
Autores principales: | Maciel, Léa Maria Zanini, Magalhães, Patrícia Künzle Ribeiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118930/ https://www.ncbi.nlm.nih.gov/pubmed/28658345 http://dx.doi.org/10.1590/2359-3997000000267 |
Ejemplares similares
-
Evaluation of thyroid nodules in the Brazilian Public Health Care System, Supplementary Health System, and Private Health System in the northeastern region of the State of São Paulo
por: Goulart, Ana Paula Figueiredo Engler, et al.
Publicado: (2020) -
Preoperative detection of TERT promoter and BRAF(V600E) mutations in papillary thyroid carcinoma in high-risk thyroid nodules
por: Giorgenon, Tatiana Marina Vieira, et al.
Publicado: (2019) -
Impact of lead exposure on the thyroid glands of individuals living in high- or low-lead exposure areas
por: Rivera-Buse, José Estefano, et al.
Publicado: (2023) -
International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma
por: Xu, Bin, et al.
Publicado: (2022) -
Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
por: Grande, Enrique, et al.
Publicado: (2013)